Basel, Switzerland

Hans Peter Maerki

USPTO Granted Patents = 37 

 

 

Average Co-Inventor Count = 7.5

ph-index = 5

Forward Citations = 56(Granted Patents)


Company Filing History:


Years Active: 2010-2021

Loading Chart...
Loading Chart...
Loading Chart...
37 patents (USPTO):

Title: Innovations and Contributions of Hans Peter Maerki

Introduction

Hans Peter Maerki, based in Basel, Switzerland, is a notable inventor with an impressive portfolio of 37 patents. His contributions to the field of pharmaceuticals and chemical compounds have led to significant advancements in therapeutic inhibitors.

Latest Patents

Among his latest innovations are the patents for difluoroketamide derivatives and trifluoromethylpropanamide derivatives, both of which act as HtrA1 inhibitors. These inventions provide novel compounds characterized by a specific general formula, which includes a range of unique compositions and outlined methods for their application in therapeutic settings. Such advancements demonstrate his commitment to improving medicinal chemistry through innovative solutions.

Career Highlights

Throughout his career, Maerki has been associated with prestigious organizations, including Hoffmann-La Roche Inc. His work at this company highlights his expertise in the pharmaceutical industry, where he has made substantial contributions to drug development and innovation.

Collaborations

Maerki has collaborated with esteemed colleagues such as Johannes Aebi and Benoit Hornsperger. These partnerships signify the importance of teamwork in the innovation process, blending ideas and skills for greater inventive outcomes.

Conclusion

In summary, Hans Peter Maerki's work in Basel has positioned him as a key figure in the field of pharmaceutical innovations. His latest patents on HtrA1 inhibitors reflect not only his inventiveness but also his dedication to addressing medical challenges through chemical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…